Needham & Company Maintains a 'Buy' on Lexicon Pharmaceuticals (LXRX); Underappreciated Given Number of Phase 2 Compounds Under Development
Go back to Needham & Company Maintains a 'Buy' on Lexicon Pharmaceuticals (LXRX); Underappreciated Given Number of Phase 2 Compounds Under Development| Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) | Delayed: 2.32 -0.02 (0.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.34 | 52 Week High | $19.62 | |||
| Open | $2.32 | 52 Week Low | $7.65 | |||
| Day High | $2.34 | P/E | N/A | |||
| Day Low | $2.27 | EPS | $-0.22 | |||
| Volume | 1,762,686 | |||||
